Table 2.
Univariate and multivariate analysis for predictive factors of overall survival.
| Univariate |
Multivariate (PMI-Model) |
Multivariate (SMI-Model) |
||||
|---|---|---|---|---|---|---|
| HR (95%CI) | p Value | HR (95%CI) | p Value | HR (95%CI) | p Value | |
| Age | 0.84 (0.55–1.27) | .410 | ||||
| Gender (male) | 1.00 (0.98–1.01) | .964 | ||||
| BMI (≥ 24 kg/m2) | 0.96 (0.68–1.35) | .816 | ||||
| Aetiology (HBV) | 1.18 (0.74–1.86) | .487 | ||||
| AFP (> 400 ng/mL) | 3.86 (2.73–5.45) | <.001 | 2.46 (1.68–3.60) | <.001 | 2.81 (1.93–4.10) | <.001 |
| Child-Pugh class (A) | 2.26 (1.43–3.58) | .001 | 2.13 (1.34–3.41) | .002 | 2.08 (1.30–3.32) | .002 |
| ALBI | ||||||
| 1 | 1.00 (reference) | |||||
| 2 | 1.43 (1.00–2.04) | .047 | ||||
| 3 | 4.28 (1.92–9.52) | <.001 | ||||
| Number of tumours (> 3) | 3.21 (2.26–4.55) | <.001 | ||||
| Maximum tumour diameter (>3 cm) | 2.43 (1.65–3.57) | <.001 | 2.01 (1.25–3.24) | .004 | 2.06 (1.29–3.29) | .002 |
| Portal vein thrombus | 3.97 (2.68–5.86) | <.001 | ||||
| Metastasis | 7.65 (4.87–12.02) | <.001 | 1.82 (1.05–3.16) | .032 | 1.99 (1.16–3.43) | .013 |
| BCLC stage | ||||||
| A | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | |||
| B | 2.17 (1.28–3.68) | .004 | 1.66 (0.97–2.87) | .067 | 1.60 (0.93–2.75) | .091 |
| C | 10.82 (6.25–18.74) | <.001 | 5.85 (3.06–11.17) | <.001 | 5.55 (2.90–10.59) | <.001 |
| SMI (low) | 0.52 (0.37–0.73) | <.001 | 0.51 (0.36–0.72) | <.001 | ||
| PMI (low) | 0.42 (0.28–0.63) | <.001 | 0.64 (0.45–0.91) | .014 | ||
HR: hazard ratio; CI: confidence interval; BMI: body mass index; AFP: α-Fetoprotein; BCLC: Barcelona Clinic Liver Cancer; SMI: skeletal muscle index; PMI: psoas muscle index.
PMI-Model: Adjusted for AFP, Child-Pugh class, maximum tumour diameter, metastasis and BCLC stage; SMI-Model: Adjusted for AFP, Child-Pugh class, maximum tumour diameter, metastasis and BCLC stage.